Astrana Health (NASDAQ: ASTH) CMO Dinesh Kumar plans June 1, 2026 exit

Rhea-AI Filing Summary

Astrana Health, Inc. disclosed that its Chief Medical Officer, Dinesh Kumar, M.D., has notified the company of his intention to resign. His resignation will be effective June 1, 2026. The company states that Dr. Kumar’s decision is not due to any disagreement with Astrana Health. The filing notes the company’s appreciation for his contributions and extends well wishes for his future endeavors.

Insights

Corporate governance analyst

Astrana reports a planned CMO departure with no stated dispute.

Astrana Health announced that Chief Medical Officer Dinesh Kumar, M.D., intends to resign effective June 1, 2026. The company explicitly notes that his resignation is not the result of any disagreement with the organization.

Leadership transitions in key medical roles can matter for strategy and clinical oversight, but this notice frames the change as orderly and amicable. Future filings may clarify any succession plans or new appointments for the Chief Medical Officer role.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Resignation effective date: June 1, 2026

1 metrics

Resignation effective date June 1, 2026 Chief Medical Officer Dinesh Kumar’s resignation

Key Terms

Chief Medical Officer, Emerging growth company, Securities Exchange Act of 1934

3 terms

Chief Medical Officer financial

"Dinesh Kumar, M.D., the Chief Medical Officer of Astrana Health, Inc."

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Securities Exchange Act of 1934 regulatory

"Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934"

FAQ

What executive change did Astrana Health (ASTH) disclose in this 8-K?

Astrana Health reported that its Chief Medical Officer, Dinesh Kumar, M.D., intends to resign effective June 1, 2026. The company noted his decision is not due to any disagreement and thanked him for his contributions and service.

When will Astrana Health CMO Dinesh Kumar’s resignation become effective?

Dinesh Kumar’s resignation as Chief Medical Officer will become effective on June 1, 2026. He notified Astrana Health of his intention to resign on May 7, 2026, providing several weeks’ notice before his departure becomes effective.

Did Astrana Health (ASTH) report any disagreement related to the CMO’s resignation?

Astrana Health stated that Dinesh Kumar’s resignation as Chief Medical Officer is not the result of any disagreement with the company. This language suggests the departure is framed as amicable and not tied to disputes over operations or policies.

What role did Dinesh Kumar hold at Astrana Health before his resignation?

Before his announced resignation, Dinesh Kumar, M.D., served as Chief Medical Officer of Astrana Health, Inc. The company’s disclosure focuses on his intention to resign and expresses appreciation for his contributions to the organization’s work.

Who signed the Astrana Health report announcing the CMO change?

The report announcing the Chief Medical Officer’s planned resignation was signed on behalf of Astrana Health by Brandon K. Sim. He is identified in the document as the company’s Chief Executive Officer and President at the time of signing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 06:06 AM Learn about SEC filing dates

false 0001083446 0001083446 2026-05-07 2026-05-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 7, 2026

ASTRANA HEALTH, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-37392	95-4472349
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

1668 S. Garfield Avenue, 2nd Floor, Alhambra, California 91801

(Address of Principal Executive Offices) (Zip Code)

(626) 282-0288

Registrant’s Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	ASTH	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 7, 2026, Dinesh Kumar, M.D., the Chief Medical Officer of Astrana Health, Inc. (the “Company”), notified the Company of his intention to resign, effective as of June 1, 2026. Dr. Kumar’s resignation is not a result of any disagreement with the Company. The Company thanks Dr. Kumar for his contributions and wishes him the best in his future endeavors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ASTRANA HEALTH, INC.
Date: May 11, 2026	By:	/s/ Brandon K. Sim
	Name:	Brandon K. Sim
	Title:	Chief Executive Officer and President

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB